Searched for
NEXAVAR DRUG
- Bayer says it will defend its intellectual property rights on cancer drug
Bayer today said it will continue to defend its IP rights while expressing disappointment at the IPAB decision to reject the firm's plea to...
- Patent drug prices to be set in negotiations with pharma companies
A panel set up to look into the pricing mechanism for patented drugs has said that prices have to be decided after deliberations with manuf...
- Pharma Department proposes negotiating patent drug rates with firms
The department is the convener of an inter-ministerial group comprising DIPP and the Health Ministry to modulate a pricing mechanism for pa...
- Intellectual Property Appellate Board postpones Bayer's compulsory licence appeal
IPAB has postponed German company Bayer AG's appeal against the grant of a compulsory licence of its patented drug Nexavar to Natco Pharma ...
- US accuses India of WTO rules violation over Nexavar: Report
The government had defended the move, with Commerce and Industry Minister Anand Sharma stating that India did not violate any WTO norms.
Cipla breached patent rights by slashing cancer drug price: Bayer PharmaBayer has not given its consent to Cipla to launch its generic Sorafenib & co's decision to cut price "is clear patent infringement," Bayer...
- No applications pending from pharmaceutical companies seeking compulsory licenses: Government
The government has clarified that no applications are pending from pharmaceutical companies seeking compulsory licences for producing low-c...
- Patented drugs: No application pending for compulsory license, says government
Amid concerns that more domestic pharma companies could seek compulsory licenses to replicate patented drugs, the government said no such a...
- Bayer challenges Nexavar generic licence order
Bayer has filed an appeal against a patents order, which allowed domestic drug maker Natco Pharma to sell a generic version of the German f...
- Natco Pharma bags licence to sell Nexavar drug; stock up
Shares of Natco Pharma extended gains for the second straight day on Tuesday after the company reported that it had received a license for ...
- Bayer drags Cipla to court over patent
German drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drug seller, to stop the Mumbai-based compa...
- SC rejects Bayer’s plea to stay Cipla’s cancer clone
The Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Baye...
- No interim stay on Cipla’s Nexavar clone
The Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Baye...
- Bayer’s bid to stay Cipla cancer drug foiled, next hearing on Oct 6
Germany's largest drug maker Bayer failed to get a court stay on Cipla from seeking permission to launch the European company’s copycat of ...
- Cipla's clone of Bayer cancer drug gets nod
This case was keenly watched by both pharma industry and health activists because it had much wider ramifications.
- Major win for Indian pharma cos as HC dismisses Bayer petition
The Delhi High Court (HC) on Tuesday dismissed German drug major Bayer Healthcare’s attempt to stop Drug Controller General of India (DCGI)...
- Cipla opposes patent for GSK’s cancer drug
Cipla has filed a grant opposition in the Kolkata patent office against GSK's newly-launched breast cancer drug on grounds of obviousness a...